We mapped all #SARSCoV2 mutations escaping key antibodies used to treat #COVID19 (biorxiv.org/content/10.110…). Surprising observations: one amino-acid mutation escapes *both* antibodies in @Regeneron cocktail & escape mutations selected in infected patient treated w cocktail. (1/8)
Specifically, @tylernstarr, Allie Greaney, Amin Addetia, and @AdamDingens used a deep mutational scanning system to determine all mutations that escape antibodies in REGN-COV2 and LY-CoV016. You can view these complete escape maps here: jbloomlab.github.io/SARS-CoV-2-RBD… (2/8)
Surprisingly, they found a single amino-acid mutation (E406W) can escapes both antibodies in REGN-COV2 cocktail. E406W isn't in structural footprint of either antibody (see image), so mechanism is unclear. But it reduces cocktail neutralization by 100-fold. (3/8)
Next, Will Hannon worked with @DrJLi@Dr_MChoudhary to examine viral evolution in a persistently infected patient treated with the Regeneron cocktail at day 145. Patient previously described in their paper here: nejm.org/doi/full/10.10… (4/8)
Analyzing deep sequencing data, found that antibody treatment was followed by changes in frequency of 5 RBD mutations, 4 of which we mapped to escape antibodies. See evolutionary dynamics below: (5/8)
Mutational dynamics show hitchhiking & competition among antibody-escape lineages, similar to persistent flu (elifesciences.org/articles/26875). We don't think comparable escape likely in typical shorter infections, but shows virus can escape via mutations we map given time. (6/8)
Finally, we used maps to see which escape mutations present in circulating #SARSCoV2. Prominent ones include Y453F (associated with mink outbreaks in Denmark / Netherlands), N439K, & others (see below). But fortunately, all low frequency right now (7/8).
Going forward, these prospective escape maps should help with assessing which viral mutations will escape important therapeutic antibodies. All the data available at links above in this thread, so please use them to help with viral surveillance! (8/8)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
After posting our pre-print mapping #SARS_CoV_2 mutations that escape Regeneron antibodies, been getting questions about implications for therapies/vaccines. I'd like to contextualize results. Summary is don't be alarmed, but pay attention to viral evolution. Long version: (1/n)
Antibody treatments consist of a single antibody (or in some cases a cocktail of a few) that bind viral spike. Since an antibody binds to one small patch of virus, typically a single mutation is sufficient to escape binding by an antibody. (2/n)
We know from other viruses this can happen. One of the best examples is Regeneron's trial of an antibody to treat RSV in infants (academic.oup.com/cid/advance-ar…). They ran an entire large / expensive clinical trial that failed. Retrospectively, the reason was obvious... (3/n)
I want to flag this important work by @SCOTTeHENSLEY, which is the best study on whether there are pre-existing antibodies to #SARSCoV2 in uninfected people that affect risk of getting #COVID19. (1/7).
Much recent speculation (eg, NY Times by @ginakolata) on if some people have pre-existing antibodies to #SARSCoV2 (eg, from common-cold CoV) that affect risk to get #COVID19. Hensley paper is a well-designed study that *actually answers* this question (2/7)
They looked at sera collected prior to #SARSCoV2. Most sera didn't have antibodies that bound #SARSCoV2 spike, but some had modest binding, mostly to S2 but a few to RBD. None of these sera were potently neutralizing, and no trend for kids to have more of them. (3/7)
In a new study (biorxiv.org/content/10.110…), we have completely mapped mutations to #SARSCoV2 that escape human antibodies, and shown that these "escape maps" predict how virus evolves under antibody pressure & inform design of escape-resistant antibody cocktails. (1/12)
Background: antibodies that target the #SARSCoV2 receptor-binding domain (RBD) are being developed as therapeutics & vaccines aim to elicit them. Among most potent RBD antibodies are set isolated by @VUMC_Vaccines, @seth_zost & Pavlo Gilchuk (nature.com/articles/s4158…) (2/12)
Key question is what mutations to #SARSCoV2 RBD escape antibody binding. Classic way to determine this is to grow virus w antibody & see what is selected. But this approach is incomplete: any given replicate stochastically selects at most 1 of possible escape mutations. (3/12)
Lots of recent discussion about #SARSCoV2 re-infections, with 2 pre-prints describing possible examples. To contextualize these re-infections, I'd like to discuss the following papers, which document same-season re-infection with influenza, and re-infection with measles (1/6).
This paper (onlinelibrary.wiley.com/doi/full/10.11…) describes an otherwise healthy 9-year old who was infected twice in a 3-month span with H3N2 influenza, without any substantial antigenic change in the virus between the two infections (residue 67 in HA1 not major antigenic site). (2/6)
Although less extensively documented due to being from an earlier era, this paper (nejm.org/doi/full/10.10…) describes at least one case (the 16-year old) of a person who appears to have been re-infected with measles virus. (3/6)
Excited to contribute to this extremely important #SARSCoV2 study by @GreningerLab that provides first direct evidence that neutralizing antibodies are a correlate of protection against #COVID19 in humans! (1/9) medrxiv.org/content/10.110…
Perhaps *the* most important question in the #SARSCoV2 field right now is what immune responses protect against re-infection in humans. Knowing the answer to this question is critical for vaccine design and epidemiology. (2/9)
Lab studies show neutralizing antibodies are protective in animals, but there isn't comparable data in humans. To address this, large & expensive studies are currently being set up.
But @GreningerLab came up with a creative way to start answering this question right now! (3/9)
To do this, @khdcrawford measured neutralizing antibody titers in longitudinal samples that @HelenChuMD's group had collected from 34 recovered individuals, whose infections ranged from asymptomatic to severe disease. (2/9)
This plot shows the dynamics for just one individual who is pretty typical: neutralizing antibody titers peak 3-4 weeks post-symptom onset, and then decline somewhat in the months following that. (See Fig 1A of pre-print for comparable data for all 34 individuals.) (3/9)